News & Updates

Older patients with cancer are unusually susceptible to polypharmacy, as well as potentially inappropriate medications and potential drug-drug interactions, reveals a study.

Treatment with thiazolidinedione (TZD) results in a significant decrease in mortality, cardiovascular events, and kidney-related adverse events among type 2 diabetes (T2D) patients with acute kidney disease (AKD), a recent study has shown.

Triplet therapy with belantamab mafodotin, bortezomib, and dexamethasone (BVd) significantly improves outcomes in relapsed or refractory multiple myeloma (RRMM), outperforming the daratumumab, bortezomib, and dexamethasone (DVd) combination therapy, according to the second interim analysis of the phase III DREAMM-7 trial.

In patients with rheumatoid arthritis (RA), high disease-associated central nervous system (CNS) pain activation on functional MRI (fMRI) brain scan may help predict clinical response to TNF inhibitor treatment, as shown in a phase III study.

Drug therapy problems (DTPs), such as adverse drug reactions (ADRs), remain highly prevalent in children with acute lymphoblastic leukaemia (ALL), a study has found.

Treatment with abrocitinib or dupilumab results in the restoration of skin barrier function in patients with atopic dermatitis (AD), but these therapies show distinct proteomic impacts, according to a study.

Treatment with inebilizumab reduced the risk of disease flares in patients with immunoglobulin G4-related disease (IgG4-RD) irrespective of sex, age, or race, according to a subgroup analysis of the phase III MITIGATE study presented at EULAR 2025.

Exposure to antibiotics within the first 3 months of life carries a modest increase in the risk of global developmental delays, especially in motor skills, cognitive function, and communication abilities, according to a study.

A recent study has shown 100-percent engagement in care and viral suppression among 25 adolescents and youth with HIV (AYHIV) being treated with long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) during follow-up.

The use of baloxavir marboxil demonstrates good tolerability in children aged <1 year, with no new safety signals seen, according to a study.